{"id":24005,"date":"2023-07-13T08:59:54","date_gmt":"2023-07-13T06:59:54","guid":{"rendered":"https:\/\/idibell.cat\/?p=24005"},"modified":"2024-11-21T15:45:02","modified_gmt":"2024-11-21T14:45:02","slug":"nou-acord-de-collaboracio-amb-licr-i-vivan-therapeutics-per-dissenyar-nous-tractaments-personalitzats-contra-el-cancer","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2023\/07\/nou-acord-de-collaboracio-amb-licr-i-vivan-therapeutics-per-dissenyar-nous-tractaments-personalitzats-contra-el-cancer\/","title":{"rendered":"Nou acord de col\u00b7laboraci\u00f3 amb l\u2019ICR i Vivan Therapeutics per dissenyar nous tractaments personalitzats contra el c\u00e0ncer"},"content":{"rendered":"<p>S\u2019ha signat una col\u00b7laboraci\u00f3 entre l&#8217;Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), l&#8217;Institute of Cancer Research (<a href=\"https:\/\/www.icr.ac.uk\/\">ICR<\/a>) de Londres, i <a href=\"https:\/\/vivantx.com\/\">Vivan Therapeutics<\/a> per desenvolupar conjuntament mol\u00e8cules que reconeguin m\u00e9s d&#8217;una diana per al tractament personalitzat del c\u00e0ncer colorectal.<\/p>\n<p>La resist\u00e8ncia als tractaments -quan el c\u00e0ncer s&#8217;adapta, evoluciona i aconsegueix esquivar la ter\u00e0pia- \u00e9s un dels reptes m\u00e9s grans en la investigaci\u00f3 del c\u00e0ncer. Tot i que un f\u00e0rmac dirigit a una diana espec\u00edfica del tumor pot resultar inicialment efica\u00e7 per aturar-ne el creixement, aquest pot desenvolupar resist\u00e8ncies amb el temps. Amb aquesta nova col\u00b7laboraci\u00f3, l&#8217;equip combinar\u00e0 la seva experi\u00e8ncia en el disseny de nous f\u00e0rmacs per contrarestar la resist\u00e8ncia als tractaments.<\/p>\n<p>Les mutacions del gen KRAS es produeixen en aproximadament el 30% dels c\u00e0ncers i s\u00f3n particularment freq\u00fcents en els adenocarcinomes de pulm\u00f3 i c\u00f2lon. S&#8217;estan desenvolupant diverses aproximacions per bloquejar l&#8217;activitat de KRAS. No obstant aix\u00f2, el KRAS mutat ha demostrat ser molt dif\u00edcil d&#8217;inhibir, i quan s&#8217;obt\u00e9, es desenvolupen resist\u00e8ncies al cap de pocs mesos. A m\u00e9s, \u00e9s poc probable que les mutacions de KRAS es produeixin soles, en la majoria dels tumors tamb\u00e9 hi ha altres mutacions que afecten altres gens oncog\u00e8nics, sovint amb un paper rellevant en la resist\u00e8ncia als medicaments i limitant l&#8217;efic\u00e0cia de l&#8217;orientaci\u00f3 \u00fanica de KRAS.<\/p>\n<p>Per tant, el desenvolupament d&#8217;eines farmacol\u00f2giques m\u00e9s eficients per inhibir KRAS \u00e9s una necessitat m\u00e8dica urgent no satisfeta. Vivan Therapeutics ha desenvolupat una col\u00b7lecci\u00f3 de models de KRAS en la mosca de la fruita, sigui sols o en combinaci\u00f3 amb altres mutacions oncog\u00e8niques, i una plataforma tecnol\u00f2gica que permet testar m\u00faltiples ter\u00e0pies amb alt rendiment.<\/p>\n<p>El <a href=\"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/cancer-de-mama\/\">Dr. Albert Antolin<\/a>, anteriorment a l&#8217;ICR i ara a l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO), utilitzar\u00e0 nous m\u00e8todes computacionals sofisticats per identificar compostos prometedors que puguin dirigir-se tant a KRAS com a altres mutacions oncog\u00e8niques. Per la seva banda, el professor <a href=\"https:\/\/www.icr.ac.uk\/our-research\/researchers-and-teams\/professor-paul-workman\">Paul Workman<\/a>, l\u00edder de l&#8217;equip de transducci\u00f3 de senyals i farmacologia molecular de l&#8217;ICR, provar\u00e0 aquests compostos prometedors en c\u00e8l\u00b7lules canceroses abans de passar als models de mosca desenvolupats per Vivan Therapeutics.<\/p>\n<p>El <strong>Dr. Antolin<\/strong> afirma: &#8220;<em>Estic molt entusiasmat amb aquesta col\u00b7laboraci\u00f3 multidisciplin\u00e0ria entre la ind\u00fastria i l&#8217;acad\u00e8mia, cadasc\u00fa aporta una experi\u00e8ncia molt diferent i complement\u00e0ria per afrontar un repte important que podria marcar una gran difer\u00e8ncia per a molts pacients amb c\u00e0ncer<\/em>&#8220;.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>S\u2019ha signat una col\u00b7laboraci\u00f3 entre l&#8217;Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), l&#8217;Institute of Cancer Research (ICR) de Londres, i Vivan Therapeutics per desenvolupar conjuntament mol\u00e8cules que reconeguin m\u00e9s d&#8217;una diana per al tractament personalitzat del c\u00e0ncer colorectal.<\/p>\n","protected":false},"author":8,"featured_media":24006,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,390,447,452,519],"tags":[],"class_list":["post-24005","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-de-mama","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-procure","category-quimica-medica-i-disseny-de-farmacs"],"publishpress_future_action":{"enabled":false,"date":"2025-01-29 05:12:31","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=24005"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24005\/revisions"}],"predecessor-version":[{"id":24007,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24005\/revisions\/24007"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/24006"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=24005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=24005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=24005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}